Funder: Alnylam Pharmaceuticals
Due Dates: May 29, 2026 (Submission deadline for RFP ALNY-RFP-TTR-13)
Funding Amounts: Up to $250,000 per proposal; multiple proposals may be awarded; actual award may be less than requested.
Summary: Supports independent educational initiatives to advance clinical decision-making in transthyretin-mediated amyloidosis (ATTR-CM), focusing on practical, real-world impact for healthcare professionals.
Key Information: Only organizations (not individuals) may apply; proposals must be submitted via the Alnylam grant portal.